The Changing Standards for FDA Oncology Approvals: Talal Hilal, MD

The FDA approval process is in place to ensure that drugs are safe and effective before they are made available to the public. But do the clinical trials that lead to approval truly ascertain whether a drug is efficacious? Fully two-thirds of anticancer drug clinical trials leading to FDA approvals between 2014 and 2019 had at least one important limitation in trial design: lack of randomization, lack of significant overall survival advantage, inappropriate use of crossover, and/or use of a...
Continue reading

Oncology Practice and COVID-19: Addressing the Challenges With Mark A. Lewis, MD

The COVID-19 pandemic has created multiple challenges to cancer care, ranging from the risk of exposure to novel coronavirus involved in having patients come to the hospital or clinic for treatment to the risks that immunosuppressive cancer treatments––and cancer itself––may pose in making patients more susceptible to COVID-19. How should these risks be balanced against the necessity of life-preserving cancer therapies? Mark A. Lewis, MD, Director of Gastrointestinal Oncology at Intermountain He...
Continue reading

Cancer Research and the Art of Spin

At oncology meetings, nearly one third of oral presentations on cancer clinical trials where the primary end point was not met presented a positive, or "not negative," conclusion about a formally negative result, according to results of a quality improvement analysis now published in JAMA Oncology. "Presentations at medical meetings have great resonance within the scientific community, especially following the diffusion of social media," write the investigators, led by first author Massimo Di Ma...
Continue reading

Closing the Gender Gap in Oncology Academic Leadership: Reshma Jagsi, MD, DPhil

​A recent study by Mudit Chowdhary, MD, and colleagues revealed that a substantial gender gap remains in academic oncology leadership: in a web query of 265 of the 273 accredited medical, radiation, and surgical oncology training programs, only 35.9% of faculty members were women. Representation was substantially lower among department chairs, with 21.7% of medical oncology programs, 11.7% of radiation oncology programs, and a mere 3.8% of surgical oncology programs chaired by women. In this int...
Continue reading

CAR T-Cell Therapy: Oncology Nurses’ Educational Needs

Pre-activity assessment data from i3 Health's nursing continuing professional development (NCPD) activity "Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies" has revealed significant baseline knowledge gaps regarding the use of chimeric antigen receptor (CAR) T-cell therapy for the treatment of patients with B-cell malignancies. Of the 584 learners who took the pretest and began the activity, 539 saw it through to completion. The learners who completed the act...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.